THERIVA BIOLOGICS, INC. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/62c14009-666f-41f0-a844-bf903a4281e0/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-23.7M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-075756 |
| FY 2024 | $-25.7M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-075756 |
| FY 2023 | $-18.3M | 2023-01-01 – 2023-12-31 | evidence 0001410578-24-000293 |
| FY 2022 | $-19.7M | 2022-01-01 – 2022-12-31 | evidence 0001410578-23-000428 |
| FY 2021 | $-14.3M | 2021-01-01 – 2021-12-31 | evidence 0001410578-22-000405 |
| FY 2020 | $-10.0M | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-032150 |
| FY 2019 | $-15.3M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-023415 |
| FY 2018 | $-13.4M | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-010592 |
| FY 2017 | $-15.2M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-010286 |
| FY 2016 | $-27.3M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-012545 |
| FY 2015 | $-43.7M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-087267 |
| FY 2014 | $-19.8M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-016433 |
| FY 2013 | $-12.3M | 2013-01-01 – 2013-12-31 | evidence 0001144204-14-019505 |
| FY 2012 | $-17.1M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-022048 |
| FY 2011 | $-8.1M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-018627 |
| FY 2010 | $-1.7M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-018627 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).